Following kidney transplants, of which almost 70,000 occur every year, the recipient’s immune system may reject the new kidney. If this rejection is not brought under control, the kidney is generally lost. Previously, immuno-suppressants have been used to treat these complications. However, this treatment can lead to infections and cancer, and is also expensive, with immunosuppressants being taken for the remainder of the patient’s lifetime.
StemSmart™ technologies have been used in two Phase 1 Clinical Trials to successfully treat kidney transplant rejection. For subjects suffering from acute rejection, the treatment was successful in over 80% of individuals.